MaxCyte (MXCT) has released an update.
MaxCyte, Inc. has granted Cynthia Collins, a non-executive director, 97,698 options and 51,679 restricted stock units as part of her appointment. These stock options have a three-year vesting schedule and an exercise price of $3.87, reflecting the closing price on the Nasdaq as of October 14, 2024. This move signals MaxCyte’s commitment to leveraging top talent for its growth in the cell therapy sector.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
